Oculis has completed the appointment of Rene Ruckert, MD, MBA, as the company’s Vice President of Product Development.
Dr. Einar Stefansson, Oculis’ Chairman and Dr. Akihiro Ohira, member of Oculis’ Scientific and Medical Advisory Board, will both present at ISOPT Clinical meeting in Berlin results of pre-clinical studies involving the Oculis platform.
At Oculis’s AGM today, Dr. Joseph Markoff, Dr. James D. Pipkin and Dr. George Mooney were elected to Oculis’ Board of Directors.
Today, Oculis’ Board of Directors approved a new Organizational Chart for the Company reflecting the recent additions to the company’s management.
The results of a phase II studies in DME of Oculis’ most advanced drug candidate, DexNP will be presented at the 2015 ARVO meeting in Denver.
Results from a pilot study on DexNP, Oculis’ most advanced drug candidate, in uveitis, will be presented at the 2014 Annual Meeting of the American Academy of Ophthalmology held in Chicago, IL, 18-21 October 2014.